Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01370356 · ClinicalTrials.gov registry record · Phase 4
A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,510
- Enrollment target
NCT01370356 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 1,510 participants.
The verdict
NCT01370356, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,510 participants
- Enrollment target
Study Summary
This study will determine whether varenicline is safe and helps people to quit smoking through reduction when they are not willing/able to make an abrupt quit attempt.
Interventions
- DRUG Placebo
- DRUG Varenicline Tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,510 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01370356
The ClinicalTrials.gov registry entry for NCT01370356 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01370356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01370356 about?
NCT01370356 is a clinical study titled "A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction". This study will determine whether varenicline is safe and helps people to quit smoking through reduction when they are not willing/able to make an abrupt quit attempt.
What is the current status of trial NCT01370356?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,510 participants. The study started on 2011-07. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01370356?
The interventions under investigation include: Placebo (DRUG), Varenicline Tartrate (DRUG).
Who is sponsoring clinical trial NCT01370356?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.